Saturday 17 October 2026
Export MMSI’s income statement to Excel — free account
Merit Medical Systems, Inc.
MMSI Healthcare Medical Instruments & Supplies
Merit Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 9.51%, EPS grew 18.2%, free cash flow fell 25.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
89.20
0.37
−0.41%
Follow MMSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
28.30 | 29.33 | 40.62 | 41.41 |
+8 more quarters Free account |
P/S ratio |
2.62 | 2.66 | 3.44 | 3.34 | |
P/FCF ratio |
20.72 | 18.87 | 24.53 | 24.19 | |
P/Operating CF |
59.73 | 100.83 | 52.93 | 65.76 | |
P/B ratio |
2.46 | 2.52 | 3.29 | 3.22 | |
Price to Tangible BV |
7.84 | 6.71 | 9.66 | 10.20 | |
EV/Sales |
2.81 | 2.82 | 3.63 | 3.57 | |
EV/EBITDA |
12.92 | 13.23 | 16.94 | 17.27 | |
EV/Operating CF |
15.63 | 14.63 | 18.51 | 19.71 | |
EV/FCF |
22.17 | 20.02 | 25.90 | 25.88 | |
Quick Ratio |
2.66 | 3.32 | 2.82 | 2.72 | |
Current Ratio |
4.20 | 5.08 | 4.34 | 4.28 | |
Net Debt/EBITDA |
3.00 | 3.13 | 3.20 | 4.35 | |
Debt/Assets |
25.71% | 27.04% | 27.33% | 27.86% | |
Debt/Equity |
0.44 | 0.45 | 0.46 | 0.48 | |
Asset Turnover |
0.58 | 0.59 | 0.59 | 0.59 | |
Operating CF/Net income |
1.79 | 0.99 | 2.59 | 2.70 | |
Capex/Depreciation |
(0.51) | (0.48) | (0.71) | (0.66) | |
Interest Coverage |
4.98 | 6.77 | 8.52 | 6.31 | |
Research and Development Expense of Revenue |
6.06% | 5.92% | 6.74% | 6.24% | |
Selling, General and Administrative Expense of Revenue |
30.85% | 30.95% | 29.15% | 31.19% | |
Intangible Assets out of Total Assets |
0.40 | 0.37 | 0.39 | 0.40 | |
Share Based Compensation of Revenue |
3.08% | 2.35% | 2.51% | 3.54% | |
Graham Net Nets |
(0.02) | 0.00 | (0.01) | (0.02) | |
Graham Number |
39.39 | 38.02 | 36.16 | 34.17 | |
Earnings Yield |
3.53% | 3.41% | 2.46% | 2.41% | |
Free Cash Flow Yield |
4.83% | 5.30% | 4.08% | 4.13% | |
Revenue per Share |
7.02 | 6.42 | 6.66 | 6.48 | |
Operating CF per Share |
1.16 | 0.68 | 1.67 | 1.27 | |
Capex per Share |
(0.30) | (0.28) | (0.43) | (0.40) | |
Free Cash Flow per Share |
0.86 | 0.40 | 1.24 | 0.87 | |
Cash per Share |
7.52 | 8.20 | 7.55 | 6.62 | |
Shareholders Equity per Share |
28.15 | 27.34 | 26.78 | 25.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.15 | 27.34 | 26.78 | 25.82 | |
Free Cash Flow |
51.09 | 23.92 | 73.20 | 51.56 | |
Working Capital |
847.31 | 884.90 | 800.39 | 755.06 | |
Capital Expenditures |
(18.19) | (16.77) | (25.31) | (23.42) | |
Net Current Asset Value |
(71.58) | 9.22 | (61.46) | (116.06) | |
EV/EBIT |
22.00 | 23.17 | 29.80 | 31.57 | |
Capex to Sales |
0.04 | 0.04 | 0.06 | 0.06 | |
Price to Operating Income |
20.55 | 21.84 | 28.23 | 29.51 | |
| Other line items | |||||
Average Receivables |
241.86 | 226.10 | 220.50 | 226.36 | |
Average Payables |
69.90 | 65.81 | 64.53 | 62.78 | |
Average Inventory |
348.71 | 335.16 | 319.88 | 318.54 | |
Average Assets |
2,724.83 | 2,593.63 | 2,552.26 | 2,504.54 | |
Average Common Equity |
1,583.93 | 1,527.58 | 1,481.83 | 1,426.41 |
Columns are period end dates